Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Tarceva

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Tarceva was produced by Roche and Astellas.

NICE knocks back Lilly’s Alimta in new setting

NICE knocks back Lilly’s Alimta in new setting In June 2011 the Institute rejected Roche's NSCLC drug Tarceva in a maintenance setting because of uncertainty over how long it is able to extend survival.

Interview: Kay Drake and Naoki Okamura, Astellas

Interview: Kay Drake and Naoki Okamura, Astellas The company has also out-licensed a non-small cell lung cancer treatment (Tarceva) and non-Hodgkin's lymphoma treatment (bendamustine) to its strategic partners, with several prospective new oncology medications

Payer focus in the personalised world of oncology and orphan diseases

Payer focus in the personalised world of oncology and orphan diseases more effective (eg Herceptin in HER2+ breast cancer, Iressa and Tarceva in EGFR mutation+ non-small cell lung cancer and Glivec in Philadelphia chromosome+ CML).

FDA expands use of Roche/ Astellas’ Tarceva in lung cancer patients

FDA expands use of Roche/ Astellas’ Tarceva in lung cancer patients New indication approved alongside companion diagnostic to detect gene mutation. More patients with lung cancer in the US will have access to Roche/ Astellas' oncology medicine Tarceva after the FDA approved ... The US regulator yesterday backed Tarceva

Research units to close as Astellas restructures

Research units to close as Astellas restructures lung cancer therapy Tarceva (erlotinib) - which was bought by Astellas in 2010.

[ Previous 5 results ] 10 11 12 13 14 15 16 17 18 19 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Page & Page

For those who can imagine better, Page & Page is home to meaningful encounters of a marketing, communication and creative kind:...

Latest intelligence

DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
This report reveals insights from the people themselves, and discusses the starting points for overcoming current challenges....
Why are new medicinal products denied reimbursement in France?
Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative...
OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
Ben Speller shares his thoughts on the value of disease specific congresses...

Infographics